Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 6, 2006

Ablynx Licenses Nanobodies to Wyeth for Clinically Validated Target

  • Ablynx and Wyeth Pharmaceuticals will team up to discover, develop, and commercialize Nanobodies® directed at the tumor necrosis factor alpha protein and its receptors that target diseases in multiple therapeutic areas, under an exclusive research collaboration and license agreement with.

    Ablynx has granted Wyeth exclusive, worldwide rights to Nanobodies targeting the clinically validated target tumor necrosis factor alpha. The companies will together advance these biologics through preclinical development.

    Potential payments to Ablynx could total up to $212.5 million for the successful development and commercialization of multiple products. This includes initial payment, research support, and milestone payments. In addition Ablynx will receive royalties on product sales.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »